Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled to take place on September 11-13, 2023 in New York, NY. Management will also be available for one-on-one meetings. Details are as follows:
H.C. Wainwright 25th Annual Global Investment Conference
Date: Monday, September 11, 2023
Time: 4:30 pm ET
Location: New York, NY and virtual
Registration Link:
The webcast will also be available for viewing and replay on the “News and Events” tab of the Company’s website (). A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Aprea
Aprea Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. Our WEE1 inhibitor is being advanced to IND submission. For more information, please visit the company website at .
The Company may use, and intends to use, its investor relations website at as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
